S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
146 Pounds of Graphite Needed for Each EV (Ad)
Stock market today: World stocks mixed as Wall St inches toward bull market
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
146 Pounds of Graphite Needed for Each EV (Ad)
Stock market today: World stocks mixed as Wall St inches toward bull market
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
146 Pounds of Graphite Needed for Each EV (Ad)
Stock market today: World stocks mixed as Wall St inches toward bull market
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
146 Pounds of Graphite Needed for Each EV (Ad)
Stock market today: World stocks mixed as Wall St inches toward bull market
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Forecast, Price & News

$4.86
-0.20 (-3.95%)
(As of 06/6/2023 ET)
Compare
Today's Range
$4.80
▼
$5.22
50-Day Range
$4.50
▼
$5.50
52-Week Range
$2.80
▼
$6.19
Volume
70,861 shs
Average Volume
51,844 shs
Market Capitalization
$59.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.15
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Gain Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
67.7% Upside
$8.15 Price Target
Short Interest
Healthy
0.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($1.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

287th out of 982 stocks

Pharmaceutical Preparations Industry

134th out of 483 stocks

See Top Rated MarketRank™ Stocks Here

GANX stock logo

About Gain Therapeutics (NASDAQ:GANX) Stock

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GANX Stock News Headlines

June 1, 2023 | finance.yahoo.com
Gain Therapeutics to Present at the Jefferies Healthcare Conference
May 20, 2023 | americanbankingnews.com
Chardan Capital Brokers Cut Earnings Estimates for Gain Therapeutics, Inc. (NASDAQ:GANX)
June 7, 2023 | Edge On The Street (Ad)
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
May 17, 2023 | americanbankingnews.com
Research Analysts Set Expectations for Gain Therapeutics, Inc.'s Q4 2023 Earnings (NASDAQ:GANX)
May 16, 2023 | americanbankingnews.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Down 7.1% in April
May 15, 2023 | msn.com
Chardan Capital Maintains Gain Therapeutics (GANX) Buy Recommendation
May 15, 2023 | markets.businessinsider.com
Where Gain Therapeutics Stands With Analysts
May 15, 2023 | markets.businessinsider.com
Analyst Expectations for Gain Therapeutics's Future
June 7, 2023 | Edge On The Street (Ad)
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
May 13, 2023 | finance.yahoo.com
Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
May 12, 2023 | finanznachrichten.de
Gain Therapeutics, Inc.: Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 12, 2023 | finance.yahoo.com
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
May 12, 2023 | finance.yahoo.com
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 8, 2023 | finance.yahoo.com
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for
May 3, 2023 | marketwatch.com
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease
May 3, 2023 | finance.yahoo.com
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 1, 2023 | msn.com
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation
May 1, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Gain Therapeutics (GANX)
April 22, 2023 | finance.yahoo.com
Gain Therapeutics, Inc. (GANX) stock forecast and price target
April 12, 2023 | finance.yahoo.com
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 1, 2023 | americanbankingnews.com
Chardan Capital Weighs in on Gain Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:GANX)
March 30, 2023 | markets.businessinsider.com
BTIG Keeps Their Buy Rating on Gain Therapeutics (GANX)
March 29, 2023 | finance.yahoo.com
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 28, 2023 | finanznachrichten.de
Gain Therapeutics, Inc.: Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 27, 2023 | americanbankingnews.com
Chardan Capital Raises Gain Therapeutics (NASDAQ:GANX) Price Target to $5.75
March 23, 2023 | finance.yahoo.com
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 22, 2023 | finance.yahoo.com
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
See More Headlines

GANX Price History

GANX Company Calendar

Last Earnings
3/23/2023
Today
6/06/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GANX
CUSIP
N/A
CIK
1819411
Web
www.gaintherapeutics.com
Phone
301-500-1556
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.15
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+67.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,590,000.00
Net Margins
N/A
Pretax Margin
-12,898.67%
Return on Equity
-92.98%
Return on Assets
-73.67%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
3.75
Quick Ratio
3.75

Sales & Book Value

Annual Sales
$140,000.00
Price / Sales
428.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
3.06

Miscellaneous

Outstanding Shares
12,330,000
Free Float
10,973,000
Market Cap
$59.92 million
Optionable
Not Optionable
Beta
0.37

Key Executives

  • Dr. Khalid Islam Ph.D. (Age 67)
    Founder & Chairman
    Comp: $60k
  • Mr. Matthias Alder LIC. IUR. (Age 57)
    LL.M., COO, CEO & Director
    Comp: $414.29k
  • Mr. Salvatore Calabrese (Age 52)
    CFO & Corp. Sec.
    Comp: $345.39k
  • Mr. Gianluca Fuggetta (Age 34)
    Principal Accounting Officer
  • Dr. Xavier Barril Ph.D.
    Chief Technology Officer
  • Dr. Manolo Bellotto Ph.D. (Age 51)
    GM & Chief Strategy Officer
  • Dr. Ana Maria Garcia-Collazo Ph.D.
    Head of Research
  • Dr. Natalia Perez-Carmona Ph.D.
    Head of Biology
  • Dr. Joanne Taylor Ph.D.
    Sr. VP of Research & Scientific Advisor
  • Dr. Terenzio Ignoni Pharm.D.
    Sr. VP of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













GANX Stock - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares.
View GANX analyst ratings or view top-rated stocks.

What is Gain Therapeutics' stock price forecast for 2023?

5 brokerages have issued 12-month price targets for Gain Therapeutics' shares. Their GANX share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $8.15 in the next year. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for GANX or view top-rated stocks among Wall Street analysts.

How have GANX shares performed in 2023?

Gain Therapeutics' stock was trading at $3.13 at the start of the year. Since then, GANX shares have increased by 55.3% and is now trading at $4.86.
View the best growth stocks for 2023 here.

Are investors shorting Gain Therapeutics?

Gain Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 55,100 shares, a drop of 7.9% from the April 30th total of 59,800 shares. Based on an average trading volume of 83,600 shares, the short-interest ratio is currently 0.7 days. Currently, 0.6% of the company's stock are short sold.
View Gain Therapeutics' Short Interest.

When is Gain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our GANX earnings forecast.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02.

When did Gain Therapeutics IPO?

(GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

What is Gain Therapeutics' stock symbol?

Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX."

Who are Gain Therapeutics' major shareholders?

Gain Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.77%), CM Management LLC (0.74%), Renaissance Technologies LLC (0.32%), Raymond James & Associates (0.17%), Dimensional Fund Advisors LP (0.15%) and Susquehanna International Group LLP (0.12%).
View institutional ownership trends.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gain Therapeutics' stock price today?

One share of GANX stock can currently be purchased for approximately $4.86.

How much money does Gain Therapeutics make?

Gain Therapeutics (NASDAQ:GANX) has a market capitalization of $59.92 million and generates $140,000.00 in revenue each year. The company earns $-17,590,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact Gain Therapeutics?

Gain Therapeutics' mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The official website for the company is www.gaintherapeutics.com. The company can be reached via phone at 301-500-1556 or via email at ir@gaintherapeutics.com.

This page (NASDAQ:GANX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -